Blogs | Tissuepathology.com

Gestalt: Why Healthcare IT Staff Augmentation Is Replacing Traditional Hiring in 2026

Erica Goodpaster — Mon, 24 Aug 2026 12:37:51 +0000

From the Gestalt blog: Healthcare IT isn’t shrinking, it’s resetting. After the surge of pandemic-era hiring, many health systems are stepping back and asking a hard question: does more headcount actually make us more agile? In 2026, with tighter margins, AI initiatives accelerating, and cybersecurity demands rising, the answer often isn’t yes. Fixed labor costs can […]

The post Gestalt: Why Healthcare IT Staff Augmentation Is Replacing Traditional Hiring in 2026 first appeared on Tissuepathology.com.

Proscia: Getting to Know Kary Rogers: A Conversation with Proscia’s Head of Support

Erica Goodpaster — Fri, 21 Aug 2026 11:58:09 +0000

From Proscia on LinkedIn When evaluating an enterprise pathology platform, many life sciences organizations and diagnostic laboratories focus on the features it offers. This makes sense since scientists and pathologists will rely on that functionality every day. At Proscia, we believe that product functionality is one important part of the experience that we deliver to […]

The post Proscia: Getting to Know Kary Rogers: A Conversation with Proscia’s Head of Support first appeared on Tissuepathology.com.

Gilead and Nucleai probe why target-positive tumors can still resist ADCs

Erica Goodpaster — Tue, 18 Aug 2026 12:06:42 +0000

Nucleai, Gilead, and target-positive tumors Antibody-drug conjugates (ADCs) have emerged as one of the busiest and most crowded niches within oncology, given their potential to use an antibody to ferry a potent cytotoxic payload toward tumor cells. The class now spans about 15 FDA-approved products, and the segment is growing steadily. Evaluate Pharma projects the ADC category […]

The post Gilead and Nucleai probe why target-positive tumors can still resist ADCs first appeared on Tissuepathology.com.

Proscia: Keeping Digital Pathology Open: The Regulatory Framework Behind Concentriq AP-Dx

Erica Goodpaster — Wed, 12 Aug 2026 12:57:04 +0000

From the Proscia blog: Interoperability in digital pathology is about more than the ability to open an image file. It means giving pathologists a consistent, trusted experience as laboratories add scanners, displays, and connected systems. Selecting a digital pathology platform for primary diagnosis is a long-term, important decision impacting lab operations and the patients who […]

The post Proscia: Keeping Digital Pathology Open: The Regulatory Framework Behind Concentriq AP-Dx first appeared on Tissuepathology.com.

StatLab: The cost of slide choice in digital pathology.

Erica Goodpaster — Mon, 10 Aug 2026 11:50:49 +0000

The latest from StatLab Background Whole slide imaging (WSI) is gaining widespread adoption in diagnostic and research pathology. While attention is often given to image clarity and scanner performance, the microscope slide itself can be an influential factor in digital pathology. Background staining, an artifact arising from residual stain retained on slide surfaces, can affect […]

The post StatLab: The cost of slide choice in digital pathology. first appeared on Tissuepathology.com.

Indica Labs: Open Science Does Not Require Open Source: The Role of Open Pathology in Research

Erica Goodpaster — Thu, 06 Aug 2026 12:36:50 +0000

From the Indica Labs blog The future of scientific discovery is increasingly shaped by the principles of open science. Researchers around the world are working to make data more accessible, experiments more reproducible, and scientific collaboration more effective. These goals have become especially important in digital pathology, where advances in whole slide imaging, multiplexed tissue […]

The post Indica Labs: Open Science Does Not Require Open Source: The Role of Open Pathology in Research first appeared on Tissuepathology.com.